GENESIS-PHARMA
12.1.2024 12:37:29 CET | Business Wire | Press release
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Backs Google’s Universal Commerce Protocol (UCP) to Enable Agentic Commerce Across Platforms2.2.2026 14:30:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, is joining Google's Universal Commerce Protocol (UCP), an open standard designed to help AI agents and commerce systems work together across the full shopping lifecycle, from discovery and purchase through post-purchase support. UCP enables consumers to shop seamlessly in AI conversations while giving agents, merchant systems, and payment providers a standardized way to interact across multiple AI platforms. The announcement builds on Klarna’s recent support for Google’s Agent Payments Protocol (AP2) and expands Klarna's multiyear partnership with Google across Google Pay, Google Store, Google Play, and Google Cloud infrastructure. Together, these efforts reflect ongoing collaboration to support open standards as AI increasingly shapes how consumers shop online. “As AI-driven shopping continues to evolve, it’s important that the underlying commerce infrastructure is built on openness, trust, and transparency,” said David S
Tastepoint by IFF Predicts Ten Flavor Trends for 20262.2.2026 14:15:00 CET | Press release
From cherry to chai spice, Tastepoint’s trend experts reveal ten flavors poised to stand out this year. Tastepoint by IFF (NYSE: IFF), a leader in innovative flavor creations and taste solutions, has identified ten flavors expected to shape the North American food and beverage landscape in 2026. These predictions spotlight flavors anticipated to trend in retail, food service and beyond throughout the coming year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202440399/en/ Flavors featured in Tastepoint by IFF's 2026 trend list. “To continue delivering product development solutions that meet consumers’ unique and changing needs, we stay attuned to industry and market trends, keeping a pulse on what’s relevant now and in the future,” said Nicole Potash, Tastepoint general manager. “Our annual flavor trend predictions reflect a vibrant mix of influences, from nostalgia-driven classics to global favorites gaining momentum in
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need2.2.2026 13:30:00 CET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced that it has entered into a Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need, reflecting AdvanCell’s strategy to build a durable pipeline of differentiated targeted alpha therapies addressing large oncology markets. The collaboration brings together 48Hour Discovery’s peptide discovery platform and AdvanCell’s 212Pb expertise to rapidly construct and advance a peptide-based radiotherapeutic program. Leveraging AdvanCell’s scalable 212Pb platform, which integrates secure isotope supply and modular manufacturing with deep expertise in developing 212Pb radioligand therapies, the program is designed to enable a rapid, repeatable path into the clinic and support the expansion of AdvanCell’s target
Umm Al Qura for Development & Construction Company Launches Unified Digital Platform for Developers in Masar Destination2.2.2026 12:34:00 CET | Press release
During its participation in the Future Real Estate Forum 2026 Umm Al Qura for Development & Construction Company, the owner, developer, and operator of Masar Destination, announced the launch of a unified digital platform for property ownership within the destination through approved developers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202971654/en/ Future Semi Arial view of Masar (Photo: AETOSWire) The new digital platform provides accurate and up-to-date information in both Arabic and English about all approved developers within Masar destination, thus enhancing transparency and establishing high levels of regulation within an integrated urban system. This initiative, which reflects the Company’s responsible approach to urban development and its commitment to preserving the unique character of place and enhancing quality of life, was launched as part of the company’s participation in Future Real Estate Forum 2026,
BRUNO to Showcase Acclaimed Lifestyle and Travel Collections at Ambiente 20262.2.2026 09:00:00 CET | Press release
Tokyo-based lifestyle company BRUNO, Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO: Tetsu Shiota), dedicated to the planning, development, and sale of lifestyle products, is pleased to announce its participation in Ambiente—the world’s leading international consumer goods trade fair held in Frankfurt, Germany. The company will showcase its two flagship brands: "BRUNO," a lifestyle brand dedicated to "enjoying life to the fullest," and "MILESTO," a premium travel brand designed for those who "live every day like a journey." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202663769/en/ Our participation in Ambiente marks a pivotal step in our global expansion strategy, as outlined in our current medium-term management plan. We are excited to introduce BRUNO and MILESTO—brands that have earned immense loyalty in Japan—to a global audience. Our exhibit showcases a curated selection of flagship products and latest inn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom